Arlo-cel Shows Promising Efficacy in Pretreated R/R Multiple Myeloma
Encouraging responses and acceptable safety were highlighted in patients with heavily pretreated relapsed/refractory multiple myeloma who received treatment with arlocabtagene autoleucel (arlo-cel; BMS-986393), according to data from a phase 1 trial ( …